Innovaud Features Work of PAT4CGT Project Consortium Partners - Limula

Dr Thomas Eaton, COO of PAT4CGT Consortium partners Limula, spoke to Innovaud News about making CGT treatments accessible to patients. In the wide-ranging interview, Dr Eaton spoke at length about the Limula, the bottlenecks limiting current CGT manufacturing and the supportive business environment in Switzerland.

In particular, Dr Eaton referenced the “safe space” that Limula has been granted to grow the business as it seeks to develop a proof of concept. Dr Eaton also discussed Limula’s long-term ambition to become a platform for providing cell therapies more broadly.

Read the full interview in full

The Limula team is developing a modular platform technology for end-to-end CGT manufacturing, based on a novel bioreactor design. Its closed and automated cell processing system has great scalability potential, supporting process development towards the commercialisation of highly personalised cancer treatments.

To achieve its ambition, Limula is working with cell therapy experts at the University of Geneva and other European clinical research centres, as well as biotechnology companies.

Limula brings deep expertise in cell processing to the PAT4CGT consortium. The company will develop key components of the sensor cassette and integrate it to their bioreactor. Limula will also develop a risk assessment dossier, establish a quality management system and create a full regulatory dossier and roadmap for the proposed PAT platform.